#USA #Mahwah, NJ #Glenmark #Allergy Relief #Olopatadine

Glenmark Therapeutics Launches Olopatadine Hydrochloride Ophthalmic Solution

On June 16, 2025, Glenmark Therapeutics Inc., a prominent player in the pharmaceutical industry, announced the introduction of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) to the US market. This new product is positioned as a competitor to existing offerings, particularly the widely recognized Pataday® Once Daily Relief.

Market Insights

According to Nielsen® data, the market for Pataday® Once Daily Relief had impressive annual sales nearing $50 million within the recent 52-week period concluding on May 17, 2025. Marc Kikuchi, President and Business Head for North America at Glenmark, remarked, "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.2%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers." This statement emphasizes Glenmark's strategic approach to expanding its product portfolio in response to consumer needs, particularly in the allergy relief segment.

Product Availability

Consumers interested in purchasing Glenmark’s Olopatadine Hydrochloride Ophthalmic Solution can find further product details and purchasing options on their official website at glenmarkpharma-us.com. Glenmark's commitment to enhancing accessibility to effective allergy treatments is evident in this launch, which aims to cater to a significant portion of allergy sufferers searching for reliable and effective relief.

About Glenmark

Founded as a research-led global pharmaceutical company, Glenmark Pharmaceuticals Ltd. has a significant presence in both branded and generic segments, alongside over-the-counter products. The company's dedication towards therapeutic areas like respiratory, dermatology, and oncology highlights its intention to improve healthcare standards continually. Glenmark operates across 80 countries and has 11 top-tier manufacturing facilities across four continents, which reinforces its global operational capabilities.

Recently, Glenmark was recognized as one of 2023's Top 100 biopharmaceutical companies based on pharmaceutical sales, according to Scrip 100 rankings. Moreover, the company appears within the Top 50 Generics and biosimilar companies as per Generics Bulletin for 2024. Furthermore, Glenmark has shown a commitment to sustainability; their greenhouse gas reduction targets have been validated by the Science Based Target initiative (SBTi) in 2023, making them one of the few pharmaceutical companies in India to achieve such a milestone.

Social Responsibility Initiatives

Glenmark's influence extends beyond just pharmaceuticals, with their CSR initiatives impacting over 3.3 million lives in the last decade. The company actively engages in community development, and this commitment reflects their overarching goal of societal improvement and well-being throughout their operational regions.

In conclusion, the launch of the Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, is not just a milestone for Glenmark but also a significant step forward for allergy relief options available in the market. With consumer demand on the rise, Glenmark is positioning itself robustly to address these needs, thereby reinforcing its market presence and commitment to healthcare innovation.